Align Technology Inc Stock Price, News & Analysis

Align Technology, Inc. (Nasdaq: ALGN) has settled its patent infringement and antitrust litigation with 3Shape A/S, which commenced in November 2017. The litigation included various claims in federal courts and before the United States Patent Trial and Appeal Board. The settlement terms are confidential, but it is not expected to materially affect Align's operations or financial results. Invisalign customers will still be able to use 3Shape scanners for case submissions outside the U.S., China, and Japan. Align remains committed to innovation in digital orthodontics.

Align Technology reported Q4 2021 revenues of $1.03 billion, a 23.6% year-over-year increase. Full year revenue reached $4.0 billion, up 59.9%. Clear Aligner revenue was $3.2 billion, while Imaging Systems and CAD/CAM Services rose to $705.5 million, marking increases of 54.5% and 90.4% respectively. Q4 diluted EPS stood at $2.40; non-GAAP diluted EPS was $2.83. The company achieved significant milestones, serving over 12 million Invisalign patients. Looking ahead, Align anticipates 2022 revenue growth of 20%-30% despite potential Omicron impacts.

Align Technology (Nasdaq: ALGN) announces significant innovations in its Invisalign system aimed at enhancing digital orthodontics. Key features include ClinCheck Live Update for real-time treatment plan modifications, the Invisalign Practice App for mobile management, and the Invisalign Personalized Plan (IPP) for streamlined treatment preferences. These enhancements are designed to improve efficiency, patient outcomes, and overall practice productivity. Align's commitment to continuous innovation is underscored by leveraging data from over 12 million cases, enhancing both the doctor and patient experience.

Align Technology (Nasdaq: ALGN) will report its fourth quarter and full year 2021 financial results on February 2, 2022, after market close. The results will be available on the company's Investor Relations website at 4:00 p.m. ET. Following this, a conference call will take place at 4:30 p.m. ET to discuss the results, accessible via an audio webcast. Tentative earnings release dates for fiscal 2022 are also announced, with the first quarter on April 27, 2022.

Align Technology has announced a significant $1 million donation to the American Association of Orthodontists Foundation (AAOF), aimed at enhancing orthodontic education and research. This donation, to be distributed over five years, reflects Align's commitment to advancing the science of orthodontics. The AAOF, since its inception, has awarded $14.6 million for educational and research initiatives, benefiting orthodontic professionals and their patients. Align has been a corporate partner with the AAOF since 2017, demonstrating ongoing support for the orthodontic community.

Align Technology (Nasdaq: ALGN) announces its participation in upcoming financial conferences, with presentations available for streaming on their Investor Relations website. The company will be featured at the Jefferies London Healthcare Conference on November 18, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, where key executives will present insights. Align Technology specializes in innovative solutions for orthodontics and restorative dentistry, including the Invisalign system and iTero scanners.

Align Technology has opened its 2022 Research Award Program, offering up to $375,000 in funding to support dental research at universities globally. This initiative aims to enhance clinical and scientific research in orthodontics and dentistry. Since the program's launch in 2010, Align has allocated approximately $2.4 million in research funding. The awards, available across the Americas, EMEA, and APAC, will fund five one-year projects of up to $25,000 each. Applications are due by March 4, 2022.

Align Technology, Inc. (ALGN) has announced a new accelerated stock repurchase (ASR) agreement with Citibank to repurchase $100 million of its common stock. This repurchase is part of Align's $1 billion stock repurchase program initiated on May 13, 2021. Under this agreement, Align will initially receive approximately 128,100 shares, with the final share count based on the stock's average price during the ASR term. The transaction, set to complete in about three months, will be funded using Align's cash reserves, which totaled $1.2 billion as of September 30, 2021.

Align Technology announced the results of a clinical study published in the Journal of Dentistry, demonstrating that the iTero Element 5D imaging system with NIRI technology outperforms traditional bitewing radiography in detecting early enamel lesions by 66%. The study indicated a detection accuracy of 88.6% for early enamel lesions and 96.9% for carious lesions. Conducted across five dental clinics in Germany and Canada, the iTero system offers a radiation-free option for caries detection, enhancing dental assessments and treatment options for patients.